LUMEA Revenue and Competitors
Estimated Revenue & Valuation
- LUMEA's estimated annual revenue is currently $11.3M per year.
- LUMEA's estimated revenue per employee is $251,000
Employee Data
- LUMEA has 45 Employees.
- LUMEA grew their employee count by -6% last year.
LUMEA's People
Name | Title | Email/Phone |
---|
LUMEA Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $77.6M | 309 | 28% | N/A | N/A |
#2 | $13.8M | 55 | -17% | N/A | N/A |
#3 | $397.8M | 1585 | 7% | N/A | N/A |
#4 | $35.9M | 143 | 15% | N/A | N/A |
#5 | $75M | 157 | 43% | $12.8M | N/A |
#6 | $6.5M | 26 | 0% | N/A | N/A |
#7 | $9.3M | 37 | 9% | N/A | N/A |
#8 | $37.4M | 149 | -1% | N/A | N/A |
#9 | $143.1M | 570 | 9% | N/A | N/A |
#10 | $10.3M | 41 | -15% | N/A | N/A |
What Is LUMEA?
LUMEA Inc., previously known as Leavitt Medical, is dedicated to revolutionizing cancer diagnostics. Its team developed a biopsy-to-digital diagnostic platform that modernizes pathology, making diagnosis more reliable. The current practices for pathologists handling and preparing biopsies for diagnosis are inefficient, costly and have varying levels of quality standards. To solve this problem, LUMEA invented the BxChipâ„¢, BxLinkâ„¢, and DxLogic and is always in the process of testing and inventing more tools to help the modern pathologist. Learn about how each of these tools reinvents pathology at LUMEA.org. LUMEA was founded by Dr. Matthew Leavitt, a Stanford-trained pathologist who has dedicated his career to changing and improving cancer diagnostics. Its experienced employees all work together to save lives by revolutionizing diagnostic medicine.
keywords:N/AN/A
Total Funding
45
Number of Employees
$11.3M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 45 | 36% | N/A |
#2 | $3.5M | 46 | 5% | N/A |
#3 | $9.9M | 46 | 2% | N/A |
#4 | $10.9M | 47 | 7% | N/A |
#5 | $5.2M | 49 | 7% | $19.5M |